TargetMol

TL-895

Product Code:
 
TAR-T9705
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T9705-1mg1mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9705-1mL1 mL * 10 mM (in DMSO)£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9705-5mg5mg£148.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9705-10mg10mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9705-25mg25mg£325.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9705-50mg50mg£466.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T9705-100mg100mg£653.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
TL-895 is an ATP-competitive, and highly selective irreversible inhibitor of Bruton?s Tyrosine Kinase(BTK). TL-895 showed good potency with an IC50 of 1.5 nM and a Ki of 11.9 nM.
CAS:
1415823-49-2
Formula:
C25H26FN5O2
Molecular Weight:
447.5
Pathway:
Angiogenesis; Tyrosine Kinase/Adaptors
Purity:
0.98
SMILES:
C=CC(N(CC1)CCC1(CNc1ncnc(N)c1-c(cc1)ccc1Oc1ccccc1)F)=O
Target:
BTK

References

Richard D Caldwell, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655. Valeria Di Battista, et al. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int J Mol Sci